Insider · CIK 0001960596
Teri L Lawver
Files at CLDX (Celldex Therapeutics, Inc.), ALT (Altimmune, Inc.). First filing -, latest -.
In brief
Teri L Lawver files SEC Form 4 as director and officer at CLDX (Celldex Therapeutics, Inc.), and also at ALT (Altimmune, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Teri L Lawver has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jun 29, 2026 |
| May 1, 2026 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | May 1, 2026 |
| Nov 10, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award ISO (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Nov 12, 2025 |
| Sep 25, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | Sep 29, 2025 |
| Feb 24, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +69,800 | $0.00 | $0 | 69,800 | Feb 26, 2025 |
Questions about Teri L Lawver
Answered from the filings on this page, as of the latest one.
Is Teri L Lawver buying or selling?
Teri L Lawver has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Teri L Lawver's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Teri L Lawver has 0.
Where does Teri L Lawver file Form 4?
Teri L Lawver has filed Form 4 at CLDX (Celldex Therapeutics, Inc.) as SVP & Chief Commercial Officer; ALT (Altimmune, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.